Definitions
Sorry, no definitions found. Check out and contribute to the discussion of this word!
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word orally-available.
Examples
-
BioCryst currently has three novel late-stage compounds: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase PNP inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies.
unknown title 2011
-
CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme.
unknown title 2011
-
CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and has completed a Phase II trial in glioblastoma multiforme.
unknown title 2011
-
Sapacitabine CYC682, an orally-available nucleoside analogue, is currently being evaluated in a registration-directed, Phase 3 trial in front-line elderly AML and Phase 2 trials in patients with hematological malignancies and solid tumors.
unknown title 2011
-
DURHAM, N.C., Nov. 7, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, was presented with the "2011 SEBIO Deal of the Year: Venture Capital Transaction" award during a ceremony held at the conclusion of Southeast BIO's SEBIO 13th Annual Investor Forum on November 3, 2011.
unknown title 2011
-
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in cytomegalovirus (CMV).
THE MEDICAL NEWS Editors 2010
-
Dendreon also is developing an orally-available small molecule that targets
-
Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer.
-
July 28/PRNewswire/-- Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread®), due to the development of multi-drug resistance.
-
GLPG0634 is an orally-available, novel candidate drug developed by Galapagos and selective against Janus kinase (JAK) 1 and 2 targets discovered in collaboration with GSK.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.